Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212).
Arndt StahlerAndreas Jay KindChristine SersSoulafa MamloukLothar MüllerMeinolf KarthausStefan FruehaufUllrich GraevenLudwig Fischer von WeikersthalGreta SommerhäuserStefan KasperBeeke HoppeAnnika KurreckSwantje HeldVolker HeinemannDavid HorstArmin JaroschSebastian StinzingTanja TrarbachDominik Paul ModestPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Extended molecular profiling beyond RAS may have the potential to improve of the patient selection for anti-EGFR containing maintenance regimens.